IndustryCompany release

Akebia Q3: Vafseo revenue reaches $14.8M as Auryxia decline pulls total sales down to $36.9M

🇺🇸 Akebia Therapeutics, Inc. (AKBA) · Thu 05 Nov 2026

Akebia reported a $14.4M third-quarter net loss as growth in Vafseo use among dialysis patients failed to offset falling sales of Auryxia.

Akebia Therapeutics reported its third-quarter 2026 results on 5 November. Total revenue fell to $36.9M, which the company attributed to lower sales of Auryxia. The quarter ended with a net loss of $14.4M.

Vafseo (vadadustat), indicated for anaemia due to chronic kidney disease in dialysis patients, generated $14.8M in the period. About 11,500 patients were on therapy. The company's headline describes the patient count as up 140% year over year.

On the clinical side, Akebia reported positive safety data from the VOICE study and topline data from VOCAL showing non-inferiority to erythropoiesis-stimulating agents (ESAs). The summary available does not give detailed endpoints or figures for either study.

The company also dosed the first patient in a Phase 2 basket trial of ebribafusp alfa. Akebia ended the quarter with about $159.3M in cash.

What it means for your team

  • The VOCAL non-inferiority result against ESAs and the VOICE safety data are worth tracking for dialysis anaemia treatment positioning, though full datasets were not provided in the release summary.
  • Vafseo's growth to about 11,500 patients shows continued uptake in the US dialysis setting, while the Auryxia decline shows the company's revenue mix is shifting.
  • The first patient dosed in the ebribafusp alfa Phase 2 basket trial marks an early step in Akebia's pipeline beyond its renal products.

Company's press release (SEC filing): Akebia Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Akebia Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →